1 The contribution of calcitonin gene-related peptide (CGRP) to bilateral oedema formation in the rat hindpaw following an unilateral challenge with CGRP was investigated. 2 Rats were injected into the left hindpaw with either saline, CGRP or a CGRP antagonist (CGRP 8 ± 37 ). All injections were given in a double blind fashion and in a volume of 100 ml. CGRP and CGRP 8 ± 37 were administered in concentrations of 75, 150 or 300 pmol. Volumes of the right and left hindpaw were measured every hour for 5 h by plethysmometry. 3 Injection of CGRP 300 pmol into the left hindpaw resulted in a bilaterally increased hindpaw volume after 5 h as compared with the groups given saline. No changes were found in hindpaw volumes following the injection of either 75 or 150 pmol of CGRP or 75, 150 or 300 pmol of CGRP 8 ± 37 as compared with saline injection. 4 To elucidate whether or not the bilateral oedema formation was related to a release of endogenous CGRP, microdialysis of the contralateral hindpaw was carried out, and concentrations of CGRP-like immunoreactivity (-LI) were determined by radioimmunoassay and high performance liquid chromatography. Injection of CGRP 300 pmol into the left hindpaw increased the release of CGRP-LI into the right hindpaw perfusate after 4 and 5 h. No changes in CGRP-LI were detected in the right hindpaw perfusate following challenge with saline or CGRP 8 ± 37 . 5 To study the contribution of the nervous system to the contralateral release of CGRP-LI, sciatic nerve ligated and intact sham-operated rats were used. Sciatic nerve ligation but not sham-operation on the non-injected side abolished the increased release of CGRP-LI following contralateral administration of CGRP 300 pmol. 6 To study the spinal cord mechanisms resulting in the bilateral oedema formation following unilateral challenge with 300 pmol of CGRP, intrathecal pretreatment with either 10 nmol bicuculline (GABA A receptor antagonist) or 10 nmol CGRP 8 ± 37 was carried out. Bicuculline but not CGRP 8 ± 37 abolished the bilateral oedema formation induced by CGRP 300 pmol. 7 In order to study the mechanisms by which administration of CGRP 300 pmol induces oedema, CGRP 300 pmol was administered concomitantly with either 300 pmol of CGRP 8 ± 37 (CGRP receptor antagonist), or 3 nmol of promethazine (H 1 receptor antagonist), or 3 nmol of s(7)-propranolol (5-HT 1 receptor antagonist), or 3 nmol of cyproheptadine (5-HT 2 receptor antagonist) or 3 nmol of ICS 205 ± 930 (5-HT 3 receptor antagonist). Oedema formation was measured at 1, 5, 7 and 24 h. 8 Injection of CGRP 300 pmol into the left hindpaw induced a bilateral oedema formation which was still signi®cant at 24 h. Concomitant administration of either CGRP 8 ± 37 , ICS 205 ± 920 or cyproheptadine blocked the oedema formation at 24 h. No eect on oedema formation was found when CGRP 300 pmol was co-administered with either promethazine or s(7)-propranolol (H 1 and 5-HT 1 receptor antagonists, respectively). 9 The results of the present study show that both the nervous system and local in¯ammatory processes contribute to bilateral hindpaw oedema formation following unilateral challenge with CGRP 300 pmol. Our results indicate that endogenous release of CGRP following in¯ammatory response may play an important role in inducing oedema formation.
Introduction
Already in 1876 Stricker hypothesized that sensory aerent nerves might play a signi®cant role in the in¯ammatory process (Stricker, 1876) . In 1901 it was reported that nerve stimulation induces vasodilation (Bayliss, 1901) and in 1930 oedema response was shown to be due to antidromic stimulation of sensory nerves (Hinsey & Gasser, 1930) . This so-called neurogenic in¯ammation is caused by the activation of Adand C-®bres (Jancso et al., 1967; Gamse et al., 1980) resulting in the antidromic release of sensory neuropeptides. Among the sensory neuropeptides playing a major role in neurogenic in¯ammation are substance P (SP), neurokinin A (NKA) and calcitonin gene-related peptide (CGRP) (Lembeck & Holzer, 1979; Foreman, 1987; Kidd et al., 1991; Maggi, 1995) . CGRP is a very potent vasodilator and the vasodilatory response seen after sensory stimulation has been attributed mainly to the release of CGRP (Brain et al., 1985; 1986 , Escott et al., 1995 . In addition to its potent vasodilatory action, CGRP is considered to be an important modulator of oedema responses. This is supported by a study showing that an injection of a CGRP antagonist (CGRP 8 ± 37 ) inhibits neurogenically induced oedema formation (Escott & Brain, 1993) . Many vasodilating agents potentiate the oedema formation in response to other in¯ammatory mediators, most likely by increasing hydrostatic pressure in small venules where the plasma extravasation occurs (cf. Raud & Lindbom, 1994 ). This appears to be true also for CGRP, which is a very potent vasodilator with little or no ability to cause plasma extravasation alone (Brain et al., 1985; 1986; 1992; Gamse & Saria, 1985; Foreman, 1987) . In a series of studies, CGRP's potentiating eect in oedema formation was demonstrated, when administered concomitantly with SP, serotonin, histamine and other mediators of in¯ammation (Brain et al., 1985; Brain & Williams, 1988; Buckley et al., 1991a,b; . The results of experimental studies also show that the in¯uence of CGRP on oedema formation is dose and strain dependent (Karimian & Ferrell, 1994; Newbold & Brain, 1993) .
The aim of the present study was to investigate if a unilateral challenge with CGRP into the hindpaw is able to induce a bilateral oedema formation. The mechanisms behind this phenomenon are also investigated.
Methods

Experimental procedure for measuring hindpaw volume
Experiments were performed on male albino Sprague Dawley rats (B&K Universal AB, Sollentuna, Sweden) weighing 200 ± 250 g and were approved by the Karolinska Institutet local ethical committee. All rats were accustomed to the testing conditions ®ve times daily for 4 days before the experiment was run. On the day of the experiment the right and left hindpaw volumes were ®rst measured (basal values) and then the left hindpaw was injected with either saline, CGRP or CGRP 8 ± 37 . All injections were given in a randomized double-blind way and in a volume of 100 ml. CGRP and CGRP 8 ± 37 were injected in concentrations of 75, 150 and 300 pmol. CGRP 300 pmol was also given concomitantly with either 300 pmol of CGRP 8 ± 37 , 3 nmol of promethazine, 3 nmol of s(7)-propranolol, 3 nmol of cyproheptadine or 3 nmol of ICS 205 ± 930. No injection was given into the right hindpaw. Volumes of both left and right hindpaws were measured using a plethysmometer (UGO Basile, type 7150, Italy) either every hour up to 5 h, or at 1, 5, 7 and 24 h, according to the experimental protocol. Three measurements were carried out on each occasion and the average value was used for statistical analysis.
Doses of the serotonin and histamine receptor antagonists were chosen according to the data of additional experimental studies. Administration of 3 nmol of serotonin into the rat hindpaw induces oedema formation at approximately 25 ± 30% of the basal values 30 min after injection. The oedema formation was reduced following concomitant administration of serotonin with 3 nmol of either serotonin or histamine receptor antagonists used in the present study (5-HT 3 45-HT 1 4H 1 55-HT 2 ). In order to reduce in¯ammatory responses, the use of these selective serotonin and histamine receptor antagonists has been previously reported by Hua & Yaksh (1993) (for 5-HT 1 and 5-HT 3 ), Eschalier et al. (1989) (for 5-HT 3 ), Cole et al. (1995) (for 5-HT 2 ) and Hirschelmann et al. (1975) (for H 1 ).
Experimental procedure for intrathecal injection
Intrathecal administration was performed after 4 days of behavioural training. Before experimentation 2% lidocaine was injected subcutaneously into the area to be penetrated for intrathecal injection. A stainless steel needle, with an outer diameter of 0.5 mm, was then directly inserted into the subarachnoid space between the L3 ± L4 vertebrae. Ten ml of solution consisting of either saline, CGRP 8 ± 37 (10 nmol, Yu et al., 1996) or bicuculline (10 nmol, Rees et al., 1995) were infused intrathecally over 1 min. Two hours after intrathecal injection, an injection of CGRP 300 pmol was given into the left hindpaw. Hindpaw volumes were measured prior to CGRP 300 pmol injection, and hourly for 5 h following CGRP 300 pmol injection into the left hindpaw.
Experimental procedure for perfusation of the hindpaw 76 mol L 71 ) and after that for 1 h with saline/ thiorphan solution. The¯ow rate was kept at 4 ml min 71 by the use of a CMA/100 microinjection pump (CMA/Microdialysis, Stockholm, Sweden). Collection of 60 min samples on ice was begun 1 h after probe implantation and each experiment lasted for 5 h. Collected samples were frozen immediately and kept at 7708C until analysis.
To test the recovery of CGRP during the perfusation and radioimmunoassay procedures, probes were placed into a solution containing 1000 pmol of CGRP, samples were collected every hour for 5 h and analysed in the way described for the experimental procedure. The recovery coecient includes both the ability of the probe to exchange CGRP in the medium as well as the loss of neuropeptide during the radioimmunoassays procedure. The recovery of CGRP in the analysed samples was less than 2%, which means that we were able to analyse less than 2% of the total amount of CGRP in the hindpaw's perfusate.
Perfusation following either saline, CGRP or CGRP 8 ± 37 injection. Anaesthetized rats were injected into the left hindpaw with either saline, CGRP (300 pmol) or CGRP 8 ± 37 (300 pmol). The right hindpaw of the rat was perfused with thiorphan 10 76 mol L 71 as described above. Collection of 60 min samples on ice was started 1 h after probe implantation and each experiment lasted for 6 h. Following injection of either saline, CGRP or CGRP 8 ± 37 into the left hindpaw, samples of the right hindpaw perfusate were collected every hour for 5 h.
Surgical procedure for sciatic nerve ligation. To investigate the source of neuropeptide release, denervation of the right hindpaw was performed. Rats were anaesthetized with intraperitoneal chloralhydrate (350 mg kg 71 ) and the right sciatic nerve was cut. Control rats were sham operated. Experimentation took place 1 week to 10 days after the denervation. Both ligated and sham-operated rats received 300 pmol of CGRP into the left hindpaw. The perfusation technique used was identical with that used for intact rats.
Radioimmunoassay
Calcitonin gene-related peptide (CGRP)-LI was analysed using antiserum CGRPR8 raised against conjugated rat CGRP. HPLC-puri®ed 125 I-Histidyl rat CGRP was used as radioligand, and rat CGRP as standard. The cross-reactivity of the assay to SP, neurokinin A, neurokinin B, neuropeptide K, gastrin, neurotensin, bombesin, neuropeptide Y and calcitonin was less than 0.01%. Cross-reactivity toward rat CGRP I and II was 100 and 120%, respectively. Intra-and interassay coecients of variation were 8 and 14%, respectively. The detection limit for CGRP-LI was 7.8 fmol ml
71 . The average value of two tested samples (100 ml each) of the collected perfusate was used for statistical analysis.
High liquid performance chromatography
Perfusates were pooled in a total volume of 50 ml, lyophilized and redissolved in 200 ml distilled water. Rat CGRP (2 pmol in 200 ml) was used as a standard. Reverse-phase HPLC was performed using Waters Delta Pak C18 300 A Ê , 3.9 mm615 cm column, eluted with a 40 mL linear gradient of 0 ± 40% acetonitrile. Samples were passed through Millipore GS (0.45 mm) ®lters before being injected onto the column. Fractions of 1 ml were collected at an elution rate of 1.0 ml min 71 . Each fraction was lyophilized and redissolved in 200 ml sodium phosphate buer (pH 7.4) before analysis. The fractions were assayed for immunoreactivity in the tubes used for their collection. The detection limit for the concentrated sample was 7.8 fmol ml 71 . 
Chemicals
Statistical analysis
Statistical analysis was carried out using the SPSS software (release 6). Each experimental group included 6 ± 8 rats.
Hindpaw volume. ANOVA test was used to test the dierences between the dierent treatments in hindpaw volumes expressed in percentage changes from the start of the experiment (basal values). Wilcoxons rank sum test was used to test dierences between the right and left hindpaw in the same animal. In rats pretreated intrathecally, the statistical analysis was performed using hindpaw values measured at 2 h after intrathecal injection, i.e. before CGRP 300 pmol injection.
CGRP-LI. Mann-Whitney U-Wilcoxon rank sum test was used to compare dierences in absolute concentrations of CGRP-LI found in the right hindpaw perfusate following perfusation with either saline or thiorphan. Wilcoxons rank sum test was used to test dierences within the groups following capsaicin stimulation. ANOVA test was used to test dierences between saline, CGRP and CGRP 8 ± 37 injections as well as between intact and sham-operated rats.
Results
Eects of either CGRP or CGRP 8 ± 37 injection on the hindpaw volume as compared to saline injection Injection of either 75, 150 or 300 pmol of CGRP 8 ± 37 into the left hindpaw did not generally aect the left or right hindpaw volumes. Injection of CGRP 8 ± 37 300 pmol into the left hindpaw resulted in a slight (approximately 3% from the basal values) but signi®cant decrease of the right hindpaw volume as compared to saline injected (at 2 h) and to the contralateral hindpaw (at 1 and 2 h), results not shown.
Characterization of CGRP-LI release into the hindpaw perfusate
The basal release of CGRP-LI into the hindpaw perfusate was approximately 20 fmol ml 71 , or less than 4000 fmol ml 71 (400 fmol/100 ml) when correcting for the recovery (less than 2%).
Perfusation with capsaicin. Eect of thiorphan. Perfusation of the hindpaw with capsaicin resulted in a slight but signi®cantly increased release of CGRP-LI in the presence of thiorphan. The release of CGRP-LI following stimulation with capsaicin and in the absence of thiorphan (saline only) was unchanged compared to basal release, Figure 2 .
High liquid chromatography. Reverse-phase HPLC analysis of pooled hindpaw perfusates showed an immunoreactive component eluting in the position of synthetic rat CGRP (Figure 3a and b ). An additional component that we have not identi®ed eluted early at the injection front (Figure 3a and b) .
Eect of CGRP (300 pmol) and CGRP 8 ± 37 (300 pmol) on the CGRP-LI release into the hindpaw perfusate Intact rats. Injection of CGRP 300 pmol into the left hindpaw caused an increased release of CGRP-LI into the hindpaw perfusate on the contralateral side at 4 and 5 h compared to saline injection, (Figure 4a ), and at 2, 3, 4 and 5 h compared to CGRP 8 ± 37 injection (Figure 4b ).
Operated rats. Sciatic nerve ligation abolished the increased release of CGRP-LI into the hindpaw perfusate on the ipsilateral side at 4 and 5 h in response to contralateral injection of CGRP 300 pmol, Figure 4c .
Eect of intrathecal pretreatment with either bicuculline or CGRP 8 ± 37 on bilateral oedema formation induced by unilateral challenge with CGRP 300 pmol Unilateral challenge with CGRP 300 pmol in rats intrathecally pretreated with saline, CGRP 8 ± 37 or bicuculline did not result in bilateral oedema formation, Figure 5a and b. The ipsilateral oedema formation was inhibited by intrathecal pretreatment with bicuculline, but not by saline or CGRP 8 ± 37 , (Figure 5a ,b and c). Intrathecal pretreatment with bicuculline resulted in signi®cantly reduced hindpaw volume/oedema formation in both left (injected) and right (non-injected) hindpaws compared to those pretreated with saline, and in the left hindpaw compared to those pretreated with CGRP 8 ± 37 ( Figure  5b and c). Eects of CGRP (300 pmol) administered either alone or concomitantly with CGRP-; histamine-or serotonin-receptor antagonists on hindpaw volumes during 24 h Administration of CGRP 300 pmol into the left hindpaw induced bilateral oedema formation approximately at 7 ± 9% after 24 h when compared with saline injection (Figure 6 ). There was a signi®cant dierence between the right and the left hindpaw in both groups at 1 h after injection, but not at 5, 7 and 24 h (signi®cance is not indicated in Figure 6 ).
Injection of CGRP 300 pmol concomitantly with CGRP 8 ± 37 300 pmol into the left hindpaw signi®cantly decreased both injected and non-injected hindpaw volumes at 24 h compared with the CGRP 300 pmol injection, Figure 6 . In rats injected with CGRP together with CGRP 8 ± 37 , the non-injected hindpaw volume was signi®cantly less increased at 24 h than the injected hindpaw.
Concomitant administration of H 1 and 5-HT 1 receptor antagonists had no eect on oedema formation induced by CGRP 300 pmol (Figure 7a ). CGRP 300 pmol-induced oedema formation was reduced at 24 h when CGRP was co- administered with 5-HT 2 and 5-HT 3 receptor antagonists (Figure 7b ).
Discussion
One of the most striking ®ndings of the present study was a bilateral oedema formation following unilateral challenge with CGRP 300 pmol. Increased concentrations of CGRP-LI at the time of oedema formation have been found at the present study, suggesting a contribution from endogenously released CGRP. In the present study we used thiorphan to increase the recovery of CGRP-LI found. It has been previously demonstrated that thiorphan increased release of CGRP-LI from the peripheral nerve endings in guinea-pig cerebral venous sinuses (Tramontana et al., 1991) , indicating that endogenous neuropeptides are involved in CGRP metabolism in vivo (Maggi & Giuliani, 1994) . The contralateral release of CGRP-LI in the present study was blocked by nerve ligation, suggesting that the bilateral changes seen were due to neurogenic mechanisms. This is supported by the ®nding that intrathecal pretreatment with bicuculline prevented the ipsilateral and bilateral oedema formation. Recently, Sluka et al. (1995) reported that an acute peripheral in¯ammation results in dorsal root re¯exes causing eerent activity in both myelinated an unmyelinated nerve ®bres (Sluka et al., 1995a,b) . These re¯exes could be reduced by intrathecal administration of the GABA A receptor antagonist, bicuculline (Rees et al., 1995) . The physiological signi®cance of these re¯exes has been speculated upon (Ochoa & Serra, 1995; Sluka et al., 1995a,b) . The present results clearly suggest that these re¯exes contribute to oedema injected group, injected hindpaw and (~) non-injected hindpaw. *Denotes signi®cant dierence in injected hindpaw volumes between the saline and CGRP 300 pmol groups. +denotes signi®cant dierence in non-injected hindpaw volumes between the saline and CGRP 300 pmol groups (P50.05, n=6). #Denotes signi®cant dierence in both injected and non-injected hindpaw volumes between the CGRP and CGRP+CGRP 8 ± 37 groups. }Denotes signi®cant dierence between the ipsi-and contralateral side of rats injected with CGRP+CGRP 8 ± 37 (P50.05, n=6). formation. In the present study the intrathecal pretreatment with saline or CGRP 8 ± 37 also inhibited the bilateral but not the ipsilateral oedema formation. It may be suggested that this blocking eect is due to the vehicle volume or dilution of neurogenic substances involved in the transmission at the spinal cord. However, intrathecal pretreatment with bicuculline reduced the bilateral hindpaw oedema formation, suggesting that dorsal root and spinal cord re¯exes as well as central mechanisms have a tonic in¯uence on peripheral aerent nerve activity. It has been reported that 75% of primary sensory aerents innervating the cat knee joint have a resting activity (Schaible & Schmidt, 1983) which possibly bring about the release of neuropeptides, including CGRP in the peripheral tissue. This is supported by our previous and present results showing a basal release of CGRP and other neuropeptides in knee joint synovial perfusate (Bileviciute et al., 1994 (Bileviciute et al., , 1996 . The functional role of this basal release could be to maintain blood circulation (Maggi, 1995) and nutrition (Jernbeck et al., 1990) in the innervated area.
In the present study the bilateral oedema formation seen after unilateral challenge with 300 pmol of CGRP had a long latency, suggesting the involvement of local in¯ammatory processes including mast cell degranulation and the release of pro-in¯ammatory mediators such as histamine and serotonin (Richardson, 1990; Schwartz et al., 1991) . Activation of blood platelets is another possible source of increased serotonin concentrations in the in¯amed tissue (Hranilovic et al., 1996; Marcenac & Blache, 1985) . It is known that histamine enhances oedema formation mainly through the activation of H 1 and H 2 receptors (Akoev et al., 1996; Schwartz et al., 1991) , and that serotonin induces plasma extravasation through 5-HT 1 -and 5-HT 3 -receptor activation (Richardson, 1990; Taiwo & Levine, 1992) . In the present study the bilateral oedema formation was blocked by 5-HT 2 and 5-HT 3 but not by histamine H 1 and 5-HT 1 receptor antagonists. These ®ndings indicate that mast cell degranulation and serotonin receptor activation are involved in CGRP induced oedema formation. It may be suggested that following the degranulation of mast cells and/or activation of blood platelets the proin¯ammatory substances are released. Thereafter, due to a close anatomical relationship between the mast cells and sensory nerves (Alving et al., 1991; Renda et al., 1992) , there is an activation of nociceptive primary aerents (Akoev et al., 1996; Herbert & Schmidt, 1992) which triggers the release of neuropeptides, including CGRP, contributing to oedema formation (Maggi, 1995) . Compared to SP, the capacity of CGRP in the activation of mast cells is less pronounced (Nilsson et al., 1990) , most likely explaining why a dose of CGRP ten times lower (30 pmol, Newbold & Brain, 1993) than presently used did not induce hindpaw oedema formation. Moreover, Newbold & Brain (1993) used this dosage to investigate a possible anti-in¯ammatory eect of CGRP, also a ®nding reported by Raud and co-workers (Raud et al., 1991) . The results of the present study suggest that higher doses of CGRP may have a pro-in¯ammatory eect. It should be stressed that challenge with saline also resulted in bilateral short-lasting oedema formation which was probably simply the re¯ex eects of the vehicle injection (Levine et al., 1985) . In the present study CGRP-induced oedema lasted 24 h, possibly due to long-lasting endogenous release of CGRP-LI into the hindpaw. This ®nding is supported by our previous studies demonstrating long-lasting (24 h) release of neuropeptide-LI in the rat central and peripheral nervous systems following an acute challenge (Bileviciute et al., 1994 (Bileviciute et al., , 1996 (Bileviciute et al., , 1997 .
The oedema formation in the present study was also blocked at 24 h by concomitant administration of CGRP with CGRP 8 ± 37 , indicating that CGRP receptors contribute to oedema formation. It is known that CGRP-receptors may be divided into CGRP 1 and CGRP 2 where the CGRP 1 -is the receptor more sensitive to CGRP 8 ± 37 (Poyner, 1992) . Since the contralateral oedema formation was blocked by CGRP 8 ± 37 , it may be suggested that the CGRP 1 -receptor is related to oedema formation. It has been shown that CGRP 8 ± 37 blocks vasodilation induced by electrical nerve stimulation (Escott & Brain, 1993) , supporting the role of neurogenically released CGRP in blood¯ow regulation. However, it is also possible that CGRP 8 ± 37 reduces directly or indirectly the aerent input in the primary sensory neurons, resulting in decreased spinal cord and contralateral aerent activity (unpublished observations).
In the present study the concomitant administration of CGRP 300 pmol with either CGRP 8 ± 37 or serotonin receptor antagonists reduced oedema formation only at 24 h. This may indicate that CGRP induces vasoactive eects acting through several receptors. Indeed, pretreatment of the hindpaw with dexamethasone 17 h before CGRP 300 pmol injection signi®cantly abolished oedema formation from the start of the experiment (unpublished data), supporting an involvement of local in¯ammatory mechanisms in oedema formation mainly through mast cells mediator release.
It is interesting to note that following host defence responses induced by either i.p. injection of IL-1 (Bileviciute et al., 1994) or low doses of Freund's adjuvant (Bileviciute et al., 1996) , an acute release of CGRP is commonly found in comparison with that of other neuropeptides (SP, NKA and NPY). The acute release of neuropeptides following an acute challenge indicates an early activation of the nervous system, possibly playing an important role in general host defence responses. Bilateral oedema formation found in the present study may be a part of the general nervous system activation following challenge. However, our unpublished studies indicate that contralateral administration of CGRP 300 pmol, in contrast to 3 nmol of 5-HT, did not cause a detectable release of SP-LI into the hindpaw perfusate. Moreover, no changes were found in hindpaw withdrawal latency to mechanical or thermal stimulation following CGRP 300 pmol injection (unpublished results). Predominant release of CGRP-LI in muscle perfusate was demonstrated during physical exercise in rats (Bucinskaite et al., 1998) . This release of CGRP-LI under physiological non-in¯ammatory circumstances is suggested to contribute to muscle hyperaemia during physical exercise (Yamadama et al., 1997) .
In conclusion, an unilateral injection of CGRP into the hindpaw of the rat induces a bilateral oedema formation, which is dependent on both neurogenic and local in¯ammatory mechanisms. Neuronally released CGRP-LI may be involved in mediating the contralateral oedema formation and play an important role in both non-in¯ammatory and in¯ammatory situations in vivo.
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